Simufilam hydrochloride is under clinical development by Cassava Sciences and currently in Phase III for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase III drugs for Dementia Associated With Alzheimer’s Disease have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Simufilam hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Simufilam hydrochloride overview
Simufilam (formerly known as sumifilam) is under development for the treatment of Alzheimer’s disease dementia and pituitary tumor. The drug candidate is administered through oral route. The drug candidate is a small molecule. It targets scaffolding protein filamin A (FLNA).
Cassava Sciences overview
Cassava Sciences, formerly Pain Therapeutics, is a clinical-stage biopharmaceutical company that develops drugs for the treatment of neuroinflammation and neurodegenerative diseases, with a special focus on Alzheimer’s disease. The company’s lead product candidate Simufilam is a small molecule being developed in phase 3 clinical trials for treatment of Alzheimer’s disease. The clinical trials are conducted in phase3 studies such as Rethink-ALZ and Refocus-ALZ. It is also investigating SavaDx, a blood-based diagnostic for detection of Alzheimer’s disease. Major investors include national institute of health of health (NIH), National Institute on aging (NIA). Cassava Sciences is headquartered in Austin, Texas, the US.
For a complete picture of Simufilam hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
